DIPROLENE AF Rx
Generic Name and Formulations:
Bethamethasone, augmented (as dipropionate) 0.05%; crm.
Merck & Co., Inc.
Indications for DIPROLENE AF:
≥13yrs: apply thin film 1–2 times daily; max 50g/week. Lotion: apply a few drops 1–2 times daily; max 50mL/week; max 2 consecutive weeks' treatment per course. Discontinue when control is achieved. Do not occlude.
<13yrs: not recommended.
Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis or on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Erythema, folliculitis, pruritus, vesiculation; contact dermatitis (discontinue if irritation occurs), HPA axis suppression (esp. in children); rare: Cushing's syndrome, hyperglycemia. Also for AF crm: stinging, skin atrophy, telangiectasia, bruising, shininess.
Oint, AF crm—15g, 50g; Lotion—30mL, 60mL
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- Daily Alcohol Use May Drive Chronic Pain in Adults With HIV
- Tools to Address the Opioid Crisis
- AHA/ACC Release Updated Guidelines for Cholesterol Management
- Women Fed Soy Formula as Infants More Likely to Experience Menstrual Pain